Roberto Nitsch

Roberto Nitsch

Company: AstraZeneca

Job title: Associate Director


VIRTUAL: Innovating CRISPR Gene Editing Safety Assessments 11:30 am

Most gene editing applications carry the risk of unfavourable outcomes The level of unwanted gene editing consequences is still highly unknown The safety of gene therapies depends on the accuracy of editing detectionRead more

day: Day One

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.